Immobilization, aging
Conditions
Interventions
The experimental trial is composed of 7 weeks of n-3 PUFA or placebo supplementation, including 4 weeks of pre-immobilization, 1 week of single leg immobilization, and 2 weeks of recovery. At t=-28 d,
Sponsors
McMaster University, Canada
Eligibility
Inclusion criteria
Inclusion criteria: 1) Generally healthy, non-smoking, as assessed by questionnaire 2) Willing and able to provide informed consent 3) Men age 55-75 years 4) BMI between 22 and 33 kg/m2 5) Mini-Mental State Exam (MMSE) score > 20
Exclusion criteria
Exclusion criteria: 1) Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigators, would compromise the ability to comply with the study requirements 2) History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer, or carcinoma in situ with no significant progression over the past 2 years 3) Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral n-3 PUFA supplement ingestion and/or assessment of safety and study objectives 4) Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing) 5) Participation in a study of an investigational product less than 60 days or 5 half-lives of the investigational product, whichever is longer, before enrollment in this study 6) Hypersensitivity to the test product 7) Excessive alcohol consumption (>21 units/week) 8) Prior gastrointestinal bypass surgery 9) History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy 10) Personal or family history of clotting disorder or deep vein thrombosis 11) Concomitant use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), or any anabolic steroid
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the impact of n-3 PUFA supplementation on muscle disuse atrophy and recovery from 7 d of single leg immobilization | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) To determine the effects of n-3 PUFA supplementation on muscle strength 2) To determine the effects of n-3 PUFA supplementation on muscle protein synthesis during immobilization and recovery | — |
Contacts
Public ContactStefan Gorissen
Department of Kinesiology - McMaster University
Outcome results
None listed